21
Participants
Start Date
June 1, 2017
Primary Completion Date
March 31, 2035
Study Completion Date
March 31, 2035
TBI-1501
"Phase-I portion:~Cyclophosphamide is administered for conditioning medication of TBI1501, that is CD19-CAR-T cells, (cohort -1: 3×10\^5 cells/kg, cohort 1: 1×10\^6 cells/kg, cohort 2: 3×10\^6 cells/kg).~Phase-II portion:~Recommended dose of Phase-II part will be administered. Cyclophosphamide will be administered as conditioning. The end of study will be Week 52 after administration of TBI-1501."
Akita University Hospital, Akita
University Of Fukui Hospital, Yoshida
Kyushu University Hospital, Higashiku
Hokkaido University Hospital, Sapporo
Kobe City Medical Center General Hospital, Kobe
Mie University Hospital, Tsu
Tohoku University Hospital, Sendai
Okayama University Hospital, Okayama
Jichi Medical University hospital, Shimotsuke-shi
Cancer Institute Hospital Of JFCR, Kōto
The Institute of Medical Science, The University of Tokyo, Minato-ku
Takara Bio Inc.
INDUSTRY